Status:
COMPLETED
Telephone-Based Intervention to Treat Depression and Anxiety in Hispanic Cancer Survivors
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Survivorship
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this research is to assess the feasibility of administering a telephone-based intervention to treat depression and anxiety in Hispanic cancer survivors.
Detailed Description
Primary Objectives * To assess the feasibility (participation, accrual, retention, adherence) of administering the intervention in Hispanic cancer survivors. * To culturally adapt an existing behavio...
Eligibility Criteria
Inclusion
- Inclusion: age greater than or equal to 18 years;
- Self-identify as Hispanic ethnicity
- Score greater than or equal to 10 on the General Anxiety Disorder (GAD)-7 and/or greater than or equal to 8 on the Patient Health Questionnaire (PHQ)-9
- History of (1) treated (newly diagnosed or recurrent) solid tumor cancers (Stage I, II, or III); (2) any stage lymphoma (Hodgkin's or non-Hodgkin's); (3) acute leukemia in remission for more than a year; (4) chronic myelogenous leukemia with stable disease (chronic phase disease); or (5) chronic lymphocytic leukemia (CLL) not requiring treatment or a change in treatment for more than 6 months.
- 6-60 months post-treatment (surgery, chemotherapy, and/or radiation therapy) for cancer (If only received active surveillance for prostate cancer or lymphoma with no other cancer treatment, participant is ineligible.) The timeframe applies to the most recent completion of treatment if a participant had a cancer recurrence. It is acceptable to be on hormonal/maintenance therapies.
- Must be able to speak, read, and understand Spanish or English.
- Resides in North Carolina.
Exclusion
- Current psychotherapy \[regular appointment(s) with a mental health provider within the last 30 days\]
- Self-reported active alcohol or substance abuse within the last 30 days
- Past history of prostate cancer or non-Hodgkin's lymphoma with only active surveillance (i.e., no surgery, chemotherapy, or radiation therapy)
- Progressive cancer
- Global cognitive impairment based on self-reported diagnosis of dementia.
- Self-reported psychotic symptoms in the last 30 days (Item in Screening Form: "Have you seen things that aren't really there or have you heard voices when no one else was around within the last 30 days?")
- Active suicidal ideation with plan and intent
- Any change in psychotropic medications within the last 30 days
- Hearing loss that would preclude participating in telephone sessions (determined by brief hearing assessment administered by research staff). Individuals who can compensate for hearing loss through the use of a hearing device or TDD phone, and through the use of such devices are able to communicate with the study therapist by telephone, will be included. If the therapist cannot communicate with the participant by telephone, the participant will be excluded.
- Failure/inability/unwillingness to provide names and contact information for two family members or friends to serve as emergency contacts during the course of the study.
Key Trial Info
Start Date :
January 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04430335
Start Date
January 4 2021
End Date
February 1 2022
Last Update
August 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157